dc.contributor.advisor |
Peter Smith |
en |
dc.contributor.author |
Ravichandran, Archana |
en |
dc.date.accessioned |
2020-09-20T22:17:46Z |
en |
dc.date.available |
2020-09-20T22:17:46Z |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/52989 |
en |
dc.description |
Full Text is available to authenticated members of The University of Auckland only. |
en |
dc.description.abstract |
In contrast to other R&D intensive industries, biotechnology firms invest a significantly higher portion of revenues in R&D, and as a result, they tend to place extensive importance on the use of patents to protect core IP (Burrone, 2006). A typical IP strategy primarily involves patent procurement and little effort is executed in ensuring the patent is of commercial significance. In the knowledge-based economy, IP is more a strategic issue, than a legal one and this typical IP strategy is limited in helping firms achieve competitive advantage (Smith & Hansen, 2002). Strategic management of IP literature places importance on having an integrated approach to IP management where the IP strategy is managed according to business strategy and objectives, i.e. an integrated IP strategy and business strategy (Al-Aali & Teece, 2013; Bader et al., 2012; Lang, 2001; Ikujiro Nonaka & Teece, 2001a; Pike et al., 2005; Smith & Hansen, 2002). Some established firms have recognised that the absence of integration practices can lead to poor short-term and long-term firm outcomes and impair firm performance. This thesis hopes to contribute to a potentially new dimension of IP strategy and business strategy integration literature, with a focus on new venture biotechnology firms. The study seeks to answer the question 'how (and if) are new venture biotechnology firms integrating their IP strategy and business strategy?'. A qualitative, exploratory, multiple case study research design was adopted. Six new venture biotechnology firms were recruited using convenience sampling. The use of semi-structured interviews facilitated data collection from participants who were all in executive positions in their respective firms. Protocols to ensure reliability, validity and accuracy of the data collected were incorporated as part of the research design. The primary data analysis was done inductively through steps guided by (Gioia et al., 2013) where codes were categorised into 1st order concepts, 2nd order themes and broad and aggregate dimensions. The results of the data analysis were presented through three main models: The summary model, the case-by-case comparison and the integration spectrum model. These models led to the emergence of three major findings and two minor findings of this study. All these findings revolved around the innovation paradigms and innovation orientations of firms. A consistent relationship emerged between the overarching innovation paradigm governing firm activities to the degree of integration activities taking place within firms. |
en |
dc.relation.ispartof |
Masters Thesis - University of Auckland |
en |
dc.relation.isreferencedby |
UoA99265312513502091 |
en |
dc.rights |
Restricted Item. Full Text is available to authenticated members of The University of Auckland only. |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
http://creativecommons.org/licenses/by-nc-sa/3.0/nz/ |
en |
dc.title |
Exploring Business Strategy and IP Strategy Intergration in New Venture Biotechnology Firms: The Link to Innovation |
en |
dc.type |
Thesis |
en |
thesis.degree.discipline |
Bioscience Enterprise |
en |
thesis.degree.grantor |
The University of Auckland |
en |
thesis.degree.level |
Masters |
en |
dc.date.updated |
2020-07-27T09:19:45Z |
en |
dc.rights.holder |
Copyright: the author |
en |
dc.identifier.wikidata |
Q112953556 |
|